Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome.
Recombinant interleukin 2 (rIL2) was administered to a patient with Wiskott-Aldrich syndrome for the treatment of an intractable facial herpetiform lesion. This treatment appeared to be effective in suppressing the virus activity. At the same time, a transient improvement of the chronic eczematoid dermatitis was observed. During rIL2 administration, the CD3+ and CD4+ subsets of peripheral blood lymphocytes increased in number. These changes might play an important role in the induction of anti-viral immunity and in the improvement of dermatitis.
Azuma
H
H
Department of Paediatrics, Asahikawa Medical College, Hokkaido, Japan.
Sakata
H
H
Saijyou
M
M
Okuno
A
A
D017252:CD3 Complex; D015704:CD4 Antigens; D002648:Child; D002908:Chronic Disease; D004485:Eczema / Q000150:complications / Q000628:therapy*; D006561:Herpes Simplex / Q000150:complications / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D016176:T-Lymphocyte Subsets; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014923:Wiskott-Aldrich Syndrome / Q000150:complications / Q000276:immunology / Q000628:therapy*
D017252:CD3 Complex; D015704:CD4 Antigens; D007376:Interleukin-2; D011994:Recombinant Proteins